Group | NAF+ women (%) | P | |
---|---|---|---|
 | Multicenter trial (n = 507) | Post-trial series (n = 33) |  |
Overall | 427/507 (84) | Â | Â |
Yale trial site | 16/19 (84) | 12/33 (36) | 0.001 |
Premenopausal | 204/227 (90) | 7/10 (70) | Â |
Postmenopausal | 209/268 (78) | 5/23 (22) | <0.001 |
 | P < 0.001 | P = 0.02 |  |
No risk reduction | ND | 8/11 (73) | Â |
Risk reduction | ND | 5/22 (23) | Â |
 |  | P = 0.009 |  |
BRCA - | ND | 11/17 (65) | Â |
BRCA + | ND | 2/16 (13) | Â |
 |  | P = 0. 004 |  |